Kurve Therapeutics, Inc. news
Nasaldrugdeliveryblog.com opens lines of communication between drug delivery researchers, device manufacturers. The first blog to address issues related to nasal drug delivery formulation, research, delivery, and devices was launched by Kurve Technology, Inc., a leading developer of nasal drug delivery devices.
The blog - http://www.nasaldrugdeliveryblog.com - invites scientists, researchers and pharmaceutical executives to exchange and comment on clinical research, rece
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, t
Next-generation Medtech innovator Kurve Therapeutics begins an equity crowdfunding journey with its $50 million Regulation A+ raise.
Private investors can now invest in a company aiming to disrupt and transform a $1.3 trillion dementia market alone while benefiting millions living with neurodegenerative diseases.
Diseases like Dementia and Alzheimer’s afflict millions of people across the globe, while over 1 billion people worldwide – 1 in 6 – suffer from a n
Kurve Therapeutics, a next-generation medtech innovator focused on developing treatments for neurodegenerative diseases, announced it has filed a Form 1-A preliminary offering circular with the U.S. Securities and Exchange Commission (SEC) for a $50 million funding round [kurvetx.com/offering-circular]. Investment opportunities are now open to public investors for offers starting at $580 for 100 shares. Kurve Therapeutics is ready for Phase III clinical trials in three sep
Kurve Therapeutics has succeeded in bypassing the blood-brain barrier with their patented Controlled Particle Dispersion® (CPD) technology, creating new hope in the treatment of central nervous system disorders. The company urges CNS researchers to reach out for collaboration in providing care for this very large global population.
Led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals, neuroscience, and device t